Research location
South Bend
Indiana, United States
Research activity in South Bend
Indiana, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 409 trials and 634 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in South Bend
409 linked trials · page 1 of 9Study to Evaluate HM15275 in Subjects With Type 2 Diabetes MellitusNCT07527650 · 2026-05-18 · 1 site observation
RECRUITING
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseaseNCT07181109 · 2025-09-22 · 1 site observation
RECRUITING
E-Mindfulness Approaches for Living After Breast CancerNCT06748222 · 2025-06-27 · 1 site observation
RECRUITING
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With DapagliflozinNCT06677060 · 2025-03-14 · 1 site observation
RECRUITING
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerNCT05929768 · 2023-09-15 · 1 site observation
RECRUITING
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabNCT05812807 · 2023-06-14 · 1 site observation
RECRUITING
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialNCT05564377 · 2023-04-07 · 1 site observation
RECRUITING
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])NCT04267848 · 2020-06-16 · 1 site observation
RECRUITING
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerNCT03851445 · 2019-02-06 · 1 site observation
RECRUITING
Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related ComorbidityNCT07497880 · 2026-04-06 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam TrialNCT06671912 · 2025-02-19 · 1 site observation
SUSPENDED
A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs AloneNCT06862791 · 2025-02-18 · 1 site observation
COMPLETED
CONtiNuous glucosE Monitoring (CGM) in People wiTh Type 2 Diabetes Not on InsulinNCT06601166 · 2024-08-15 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass PreservationNCT06299098 · 2024-03-13 · 1 site observation
ACTIVE_NOT_RECRUITING
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)NCT05607550 · 2023-06-01 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast CancerNCT05705401 · 2023-05-19 · 1 site observation
ACTIVE_NOT_RECRUITING
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung StudyNCT05633602 · 2023-03-14 · 1 site observation
ACTIVE_NOT_RECRUITING
A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)NCT05755906 · 2023-02-27 · 1 site observation
COMPLETED
Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe AsthmaNCT05421598 · 2022-06-30 · 1 site observation
COMPLETED
Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes MellitusNCT05232071 · 2022-06-29 · 1 site observation
COMPLETED
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated TumorsNCT05169437 · 2022-03-15 · 1 site observation
TERMINATED
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)NCT05096663 · 2022-03-15 · 1 site observation
ACTIVE_NOT_RECRUITING
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation TherapyNCT04455750 · 2021-10-14 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a CatNCT04981717 · 2021-07-30 · 1 site observation
TERMINATED
G7 Acetabular System With Vivacit-E or Longevity Liner PMCF StudyNCT04754087 · 2021-07-07 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)NCT04625647 · 2021-04-16 · 1 site observation
ACTIVE_NOT_RECRUITING
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialNCT04457596 · 2021-03-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Pilot of Virtual Health Coaching Utilizing Lifestyle for Under-Resourced Patients With Type II DiabetesNCT04872647 · 2020-12-18 · 1 site observation
UNKNOWN
Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationNCT04432454 · 2020-09-29 · 1 site observation
COMPLETED
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLCNCT04265534 · 2020-07-24 · 1 site observation
TERMINATED
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung CancerNCT04310007 · 2020-07-13 · 1 site observation
ACTIVE_NOT_RECRUITING
Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH CirrhosisNCT04365868 · 2020-06-25 · 1 site observation
TERMINATED
NCI COVID-19 in Cancer Patients, NCCAPS StudyNCT04387656 · 2020-06-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)NCT04268550 · 2020-04-08 · 1 site observation
ACTIVE_NOT_RECRUITING
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)NCT04173507 · 2020-02-14 · 1 site observation
COMPLETED
A Study of Baricitinib in Participants With Rheumatoid ArthritisNCT04086745 · 2020-02-14 · 1 site observation
COMPLETED
Benefits of Microcor in Ambulatory Decompensated Heart FailureNCT04096040 · 2019-11-01 · 1 site observation
COMPLETED
Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationNCT03781063 · 2019-09-20 · 1 site observation
COMPLETED
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)NCT03940703 · 2019-09-19 · 1 site observation
COMPLETED
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)NCT03971474 · 2019-05-28 · 1 site observation
COMPLETED
A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate CancerNCT03871816 · 2019-04-22 · 1 site observation
COMPLETED
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)NCT03845296 · 2019-04-16 · 1 site observation
COMPLETED
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast CancerNCT03199885 · 2019-04-05 · 1 site observation
TERMINATED
Evaluation of Mammographic Breast Density in Participants with Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502NCT03609021 · 2019-02-26 · 1 site observation
TERMINATED
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid TumorsNCT03375320 · 2018-10-26 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing the Effects of Palbociclib and Fulvestrant or Letrozole for Patients 70 Years of Age of Older With Metastatic Breast CancerNCT03633331 · 2018-08-15 · 1 site observation
COMPLETED
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With DocetaxelNCT03419234 · 2018-04-26 · 1 site observation
ACTIVE_NOT_RECRUITING
Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung CancerNCT03087708 · 2018-03-23 · 1 site observation
TERMINATED
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung CancerNCT03373760 · 2017-11-30 · 1 site observation
COMPLETED
Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for SuicideNCT03185819 · 2017-10-05 · 1 site observation
COMPLETED
How to interpret this record
CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.